The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Redevelopment of a former mall, the replacement of a freeway, more hotel rooms and housing are all on the table for ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

After 3 months subscription will auto-renew at $9.95/month for 4 months.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

“Our work to bolster Wisconsin’s workforce to address our generational ... We have also welcomed major investments from ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

In addition to Wisconsin’s designation as a Tech Hub, Gov. Evers has also worked to secure multi-billion dollar investments ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...